[go: up one dir, main page]

AU2001232970A1 - A method of inducing autovaccination against hiv infection using structured treatment interruptions - Google Patents

A method of inducing autovaccination against hiv infection using structured treatment interruptions

Info

Publication number
AU2001232970A1
AU2001232970A1 AU2001232970A AU3297001A AU2001232970A1 AU 2001232970 A1 AU2001232970 A1 AU 2001232970A1 AU 2001232970 A AU2001232970 A AU 2001232970A AU 3297001 A AU3297001 A AU 3297001A AU 2001232970 A1 AU2001232970 A1 AU 2001232970A1
Authority
AU
Australia
Prior art keywords
autovaccination
inducing
hiv infection
against hiv
treatment interruptions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232970A
Inventor
Julianna Lisziewicz
Franco Lori
Georg Stephen Varga
Jianquing Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY
Original Assignee
RES INST FOR GENETIC AND HUMAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RES INST FOR GENETIC AND HUMAN filed Critical RES INST FOR GENETIC AND HUMAN
Publication of AU2001232970A1 publication Critical patent/AU2001232970A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001232970A 2000-01-28 2001-01-26 A method of inducing autovaccination against hiv infection using structured treatment interruptions Abandoned AU2001232970A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09493769 2000-01-28
US09/493,769 US20030095988A1 (en) 2000-01-28 2000-01-28 Method of inducing autovaccination against HIV infection using structured treatment interruptions
PCT/US2001/002458 WO2001054652A2 (en) 2000-01-28 2001-01-26 A method of inducing autovaccination against hiv infection using structured treatment interruptions

Publications (1)

Publication Number Publication Date
AU2001232970A1 true AU2001232970A1 (en) 2001-08-07

Family

ID=23961632

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232970A Abandoned AU2001232970A1 (en) 2000-01-28 2001-01-26 A method of inducing autovaccination against hiv infection using structured treatment interruptions

Country Status (3)

Country Link
US (1) US20030095988A1 (en)
AU (1) AU2001232970A1 (en)
WO (1) WO2001054652A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290728B1 (en) 1998-09-10 2001-09-18 Percardia, Inc. Designs for left ventricular conduit
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
AU2006263120B2 (en) * 2005-06-27 2010-02-25 Juntendo Educational Foundation Herpesvirus-derived therapeutic agent for pain
US8080369B2 (en) * 2007-08-22 2011-12-20 The Board Of Trustees Of The Leland Standford Junior University Methods for activating peripheral blood mononuclear cells (PBMCs) by administering human immunodeficiency virus (HIV) Tat under physiological oxygen levels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
AU2753700A (en) * 1999-02-03 2000-08-25 Julianna Lisziewicz Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Also Published As

Publication number Publication date
WO2001054652A3 (en) 2002-04-25
WO2001054652A8 (en) 2002-06-20
US20030095988A1 (en) 2003-05-22
WO2001054652A2 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
AU1167602A (en) Methods of therapy for hiv infection
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002323270A1 (en) Composition and method for treating hiv infection
AU2001286983A1 (en) Method of treatment
AU2002231206A1 (en) Treatment of depression
AU1408300A (en) Hiv infection inhibitors
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
AU2001232970A1 (en) A method of inducing autovaccination against hiv infection using structured treatment interruptions
AU2003217604A1 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
AU2001254561A1 (en) Immunizing against hiv infection
EP1696918A4 (en) A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor
AUPQ592100A0 (en) A method of treatment and prophylaxis
AU2002360523A1 (en) Compounds to treat hiv infection and aids
GB0008353D0 (en) Method of treating a parasitic infection
AU2002332613A1 (en) Compositions and therapeutic methods for viral infection
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2001282277A1 (en) Treatment of mycobacterial infection
AU2001264856A1 (en) Inhibitors of viral infection
PL370348A1 (en) Preparation of hiv protease inhibitors
AU2001254567A1 (en) Polypeptides for use as a vaccine and/or treatment for hiv infection
GB0016845D0 (en) Pharmaceutical composition for treatment of HIV infection
AUPR626001A0 (en) A method of treatment and/or prophylaxis
AUPQ781000A0 (en) A method of treatment